Business Context and Reporting Period
Company: Aastrom Biosciences, Inc. (Note: Input metadata referenced Vericel Corp, but the filing text identifies Aastrom Biosciences, Inc.)
Reporting Period: Quarterly Report (Form 10-Q) for the period ended December 31, 1996.
Stage: Development stage company focused on research and product development for ex-vivo production of human stem cells and hematopoietic tissues.
Key Event: Completed an Initial Public Offering (IPO) on February 7, 1997, shortly after the reporting period, raising approximately $20,000,000 net.
Key Financial Metrics
| Metric | Six Months Ended Dec 31, 1996 | Six Months Ended Dec 31, 1995 |
|---|---|---|
| Total Revenues | $253,000 | $646,000 |
| Total Costs & Expenses | $6,601,000 | $3,846,000 |
| Net Loss | $(6,162,000) | $(2,935,000) |
| Cash and Cash Equivalents (End of Period) | $4,089,000 | $6,230,000 |
| Accumulated Deficit (Inception to Dec 31, 1996) | $(33,187,000) | N/A |
| Capital Lease Obligations | $312,000 (Total) | N/A |
Revenue Composition: Revenues consist primarily of grants ($58,000 for six months ended Dec 31, 1996) and research/development agreements ($195,000). No R&D agreement revenue was recognized in the three months ended Dec 31, 1996, following the termination of a collaboration with Rhone-Poulenc Rorer (RPR) in September 1996.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 61% year-over-year for the six-month period, driven by the termination of the RPR collaboration and timing of grant awards.
- Expense Increase: Total costs and expenses increased 72% year-over-year. Research and development expenses rose from $2,982,000 to $5,710,000 due to expanded clinical and product development activities.
- Net Loss Expansion: Net loss more than doubled from $2,935,000 to $6,162,000 for the six-month period.
- Cash Burn: Cash and cash equivalents decreased by $6,878,000 during the six months ended December 31, 1996, primarily due to operating cash usage of $6,459,000.
Outlook, Risks, and Management Commentary
Outlook: Management does not anticipate net income for at least the next several years. The company expects operating losses to continue to increase as R&D programs expand. Future revenue sources are expected to remain limited to grants, milestone payments, and licensing fees.
Liquidity: While the company had $4,089,000 in cash at period end, it relies on external financing. The recent IPO (Feb 1997) provided approximately $20,000,000 in net proceeds to fund future operations.
Risks and Contingencies:
- Regulatory Approval: Success depends on FDA approval for the Aastrom Cell Production System (CPS). No assurance exists that clinical trials will demonstrate safety or efficacy.
- Commercialization: The company relies on a distribution agreement with Cobe BCT, Inc. Cobe may terminate the agreement if commercialization is unlikely by December 31, 1998.
- Supply Chain: Manufacturing relies on third parties for key components (cytokines, serum); supply interruptions could halt operations.
- Funding: If additional capital is not available, the company may be forced to delay or terminate R&D programs.
Investor Verification Checklist
- IPO Proceeds: Verify the actual net proceeds from the February 1997 IPO and the utilization of these funds in subsequent filings.
- RPR Termination Impact: Confirm the long-term financial impact of the terminated collaboration with Rhone-Poulenc Rorer and the issuance of Series E Preferred Stock.
- Cobe Distribution Agreement: Review the specific termination clauses and performance milestones in the agreement with Cobe BCT, Inc.
- Clinical Trial Status: Monitor the results of the pre-pivotal clinical trial for the Aastrom CPS, as success is critical for future revenue.
- Burn Rate: Assess the current cash burn rate against the $20 million raised in the IPO to determine runway for operations.